Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence

References

• Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006;20:1690–1700.
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Thiede C, Platzbecker U, et al Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001;7:2254–2262.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Lion T, Haas OA, et al Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003;17:1934–1942.
   Google Scholar
• Saito B, Fukuda T, Yokoyama H, et al Impact of T-cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant 2008;14:1148–1155.
   PubMed Web of Science ®Google Scholar
• Childs R, Clave E, Contentin N, et al Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234–3241.
   PubMed Web of Science ®Google Scholar
• Balon J, Halaburda K, Bieniaszewska M, et al Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant 2005;35:1083–1088.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, et al Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–3400.
   PubMed Web of Science ®Google Scholar
• Maris MB, Niederwieser D, Sandmaier BM, et al HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021–2030.
   PubMed Web of Science ®Google Scholar
• Mattson J, Uzunel M, Remberger M, et al T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-vs.-host disease after allogeneic transplantation. Transplant 2001;71:433–439.
   PubMed Web of Science ®Google Scholar
• Huss R, Deeg HJ, Gooley T, et al Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996;18:767–776.
   PubMed Web of Science ®Google Scholar
• Baron F, Baker JE, Storb R, et al Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254–2262.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999;5:192–203.
   PubMedGoogle Scholar
• Pelot MR, Pearson DA, Swenson K, et al Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999;5:133–143.
   PubMedGoogle Scholar
• Perez-Simon JA, Caballero D, ez-Campelo M, et al Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002;16:1423–1431.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Pearce L, Ho AY, et al Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007;138:517–526.
   PubMed Web of Science ®Google Scholar
• Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 2005;19:153–164.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, et al Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103:1548–1556.
   PubMed Web of Science ®Google Scholar
• Meyer RG, Britten CM, Wehler D, et al Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007;109:374–382.
   PubMed Web of Science ®Google Scholar
• Mattsson J, Uzunel M, Brune M, et al Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2001;115:935–944.
   PubMed Web of Science ®Google Scholar
• Michaelis L, Lin S, Joseph L, et al Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant 2007;40:181.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Pearce L, Ingram W, et al Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transplant 2008;41:587–588.
   PubMed Web of Science ®Google Scholar
• VanBesien K, Artz A, Smith S, et al Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728–5738.
   PubMed Web of Science ®Google Scholar
• O'Donnell PH, Artz AS, Undevia SD, et al Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). ASCO Meeting Abstracts 2008;26:7042.
   Google Scholar
• van Besien K, Kline J, Godley L, et al Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation in patients with advanced hematologic malignancies. Biol Blood Marrow Transplant 2009;15:105. (abstr)
   Web of Science ®Google Scholar
• Anonymous. ASBMT disease classifications. http://www.asbmt.org/rfi/form.html
   Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al Consensus conference on GVHD grading. Bone Marrow Transplant 1995;15:825–828.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008;26:4027–4034.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals Stat 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, et al DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580–3589.
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Martino R, Caballero D, et al Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003;31:387–392.
   PubMed Web of Science ®Google Scholar
• Baron F, Baker JE, Storb R, et al Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254–2262.
   PubMed Web of Science ®Google Scholar
• Mohty M, Avinens O, Faucher C, et al Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematol 2007;92:1004–1006.
   PubMed Web of Science ®Google Scholar
• Keil F, Prinz E, Moser K, et al Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplant 2003;76:230–236.
   PubMed Web of Science ®Google Scholar
• Marks DI, Lush R, Cavenagh J, et al The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002;100:3108–3114.
   PubMed Web of Science ®Google Scholar
• Dey BR, McAfee S, Colby C, et al Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003;9:320–329.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W, et al Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004;22:1696–1705.
   PubMed Web of Science ®Google Scholar